Details of the Drug

General Information of Drug (ID: DMA13GD)

Drug Name
Cidofovir
Synonyms
CDV; Cidofovirum; Forvade; HPMPC; Vistide; Cidofovir anhydrous; GS 0504; GS 504; GS504; Cidofovir (Vistide); Cidofovir (anhydrous); GS-0504; GS-504; Vistide (TN); Vistide, Cidofovir; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; (S)-HPMPC; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
Indication
Disease Entry ICD 11 Status REF
Cytomegalovirus infection 1D82 Approved [1]
Cytomegalovirus retinitis 9B72.00 Approved [2]
Therapeutic Class
Anti-HIV Agents
Affected Organisms
Human Immunodeficiency Virus
ATC Code
J05AB12: Cidofovir
J05AB: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A: DIRECT ACTING ANTIVIRALS
J05: ANTIVIRALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 279.19
Logarithm of the Partition Coefficient (xlogp) -3.6
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption
The absorption of drug is 100% []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.5 mL/min/kg [4]
Elimination
90% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.4 - 3.2 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 17.909 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 1% [4]
Vd
The volume of distribution (Vd) of drug is 0.537 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 170 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Apoptosis Not Available cdkn1a OT0BQQU9 [6]
Apoptosis Not Available PRPF19 OTQ1STV3 [6]
Chemical Identifiers
Formula
C8H14N3O6P
IUPAC Name
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
Canonical SMILES
C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O
InChI
InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
InChIKey
VWFCHDSQECPREK-LURJTMIESA-N
Cross-matching ID
PubChem CID
60613
ChEBI ID
CHEBI:3696
CAS Number
113852-37-2
UNII
768M1V522C
DrugBank ID
DB00369
TTD ID
D04AAW
VARIDT ID
DR00066
ACDINA ID
D00946
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Herpes simplex virus DNA polymerase UL30 (HSV UL30) TTIU7X1 DPOL_HHV11 Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [9]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
(E3-independent) E2 ubiquitin-conjugating enzyme OTHGS2VA UBE2O_HUMAN Gene/Protein Processing [10]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Gene/Protein Processing [10]
1,4-alpha-glucan-branching enzyme (GBE1) OTK2N05B GLGB_HUMAN Gene/Protein Processing [10]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [10]
3'-5' RNA helicase YTHDC2 OTYDYKDY YTDC2_HUMAN Gene/Protein Processing [10]
3-oxoacyl- synthase, mitochondrial (OXSM) OTMDWHOM OXSM_HUMAN Gene/Protein Processing [10]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2) OTLVN68B AAKB2_HUMAN Gene/Protein Processing [10]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) OTQYEXL2 F264_HUMAN Gene/Protein Processing [10]
ABC-type oligopeptide transporter ABCB9 (ABCB9) OTSOBOL5 ABCB9_HUMAN Gene/Protein Processing [10]
Adenylate kinase 4, mitochondrial (AK4) OTA0T02Q KAD4_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cidofovir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Cidofovir caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [11]
Framycetin DMF8DNE Major Increased risk of nephrotoxicity by the combination of Cidofovir and Framycetin. Alcoholic liver disease [DB94] [12]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Cidofovir and Inotersen. Amyloidosis [5D00] [12]
Kanamycin DM2DMPO Major Increased risk of nephrotoxicity by the combination of Cidofovir and Kanamycin. Bacterial infection [1A00-1C4Z] [12]
Amikacin DM5PDRB Major Increased risk of nephrotoxicity by the combination of Cidofovir and Amikacin. Bacterial infection [1A00-1C4Z] [12]
Streptomycin DME1LQN Major Increased risk of nephrotoxicity by the combination of Cidofovir and Streptomycin. Bacterial infection [1A00-1C4Z] [12]
Gentamicin DMKINJO Major Increased risk of nephrotoxicity by the combination of Cidofovir and Gentamicin. Bacterial infection [1A00-1C4Z] [12]
Netilmicin DMRD1QK Major Increased risk of nephrotoxicity by the combination of Cidofovir and Netilmicin. Bacterial infection [1A00-1C4Z] [12]
Tobramycin DMUI0CH Major Increased risk of nephrotoxicity by the combination of Cidofovir and Tobramycin. Bacterial infection [1A00-1C4Z] [12]
Etidronic acid DM1XHYJ Major Increased risk of nephrotoxicity by the combination of Cidofovir and Etidronic acid. Bone paget disease [FB85] [12]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Cidofovir and Iodipamide. Cholelithiasis [DC11] [12]
Phenylbutazone DMAYL0T Major Increased risk of nephrotoxicity by the combination of Cidofovir and Phenylbutazone. Chronic pain [MG30] [12]
Ketoprofen DMRKXPT Major Increased risk of nephrotoxicity by the combination of Cidofovir and Ketoprofen. Chronic pain [MG30] [12]
Oxaliplatin DMQNWRD Moderate Decreased renal excretion of Cidofovir caused by Oxaliplatin mediated nephrotoxicity. Colorectal cancer [2B91] [13]
Methoxyflurane DML0RAE Major Increased risk of nephrotoxicity by the combination of Cidofovir and Methoxyflurane. Corneal disease [9A76-9A78] [12]
Mefenamic acid DMK7HFI Major Increased risk of nephrotoxicity by the combination of Cidofovir and Mefenamic acid. Female pelvic pain [GA34] [12]
Pentamidine DMHZJCG Major Increased risk of nephrotoxicity by the combination of Cidofovir and Pentamidine. Fungal infection [1F29-1F2F] [12]
Amphotericin B DMTAJQE Major Increased risk of nephrotoxicity by the combination of Cidofovir and Amphotericin B. Fungal infection [1F29-1F2F] [12]
177Lu-DOTATATE DMT8GVU Major Increased risk of nephrotoxicity by the combination of Cidofovir and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [12]
Zidovudine DM4KI7O Moderate Decreased metabolism of Cidofovir caused by Zidovudine. Human immunodeficiency virus disease [1C60-1C62] [12]
Givosiran DM5PFIJ Major Increased risk of nephrotoxicity by the combination of Cidofovir and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [12]
Balsalazide DM7I1T9 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Balsalazide. Indeterminate colitis [DD72] [12]
Meclofenamic acid DM05FXR Major Increased risk of nephrotoxicity by the combination of Cidofovir and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [12]
Methotrexate DM2TEOL Major Increased risk of nephrotoxicity by the combination of Cidofovir and Methotrexate. Leukaemia [2A60-2B33] [12]
Ibandronate DM0QZBN Major Increased risk of nephrotoxicity by the combination of Cidofovir and Ibandronate. Low bone mass disorder [FB83] [12]
Moxetumomab pasudotox DMN63DZ Major Increased risk of nephrotoxicity by the combination of Cidofovir and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [12]
Clofarabine DMCVJ86 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Clofarabine. Mature B-cell lymphoma [2A85] [12]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Cidofovir and Exjade. Mineral absorption/transport disorder [5C64] [12]
Gallium nitrate DMF9O6B Major Increased risk of nephrotoxicity by the combination of Cidofovir and Gallium nitrate. Mineral excesses [5B91] [12]
Zoledronate DMIXC7G Major Increased risk of nephrotoxicity by the combination of Cidofovir and Zoledronate. Mineral excesses [5B91] [12]
Rofecoxib DM3P5DA Major Increased risk of nephrotoxicity by the combination of Cidofovir and Rofecoxib. Osteoarthritis [FA00-FA05] [12]
Valdecoxib DMAY7H4 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Valdecoxib. Osteoarthritis [FA00-FA05] [12]
Diclofenac DMPIHLS Major Increased risk of nephrotoxicity by the combination of Cidofovir and Diclofenac. Osteoarthritis [FA00-FA05] [12]
Naproxen DMZ5RGV Major Increased risk of nephrotoxicity by the combination of Cidofovir and Naproxen. Osteoarthritis [FA00-FA05] [12]
Carboplatin DMG281S Major Increased risk of nephrotoxicity by the combination of Cidofovir and Carboplatin. Ovarian cancer [2C73] [12]
Etodolac DM6WJO9 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Etodolac. Pain [MG30-MG3Z] [12]
Diflunisal DM7EN8I Major Increased risk of nephrotoxicity by the combination of Cidofovir and Diflunisal. Pain [MG30-MG3Z] [12]
Ibuprofen DM8VCBE Major Increased risk of nephrotoxicity by the combination of Cidofovir and Ibuprofen. Pain [MG30-MG3Z] [12]
Nabumetone DMAT2XH Major Increased risk of nephrotoxicity by the combination of Cidofovir and Nabumetone. Pain [MG30-MG3Z] [12]
Piroxicam DMTK234 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Piroxicam. Pain [MG30-MG3Z] [12]
Streptozocin DMOF7AT Major Increased risk of nephrotoxicity by the combination of Cidofovir and Streptozocin. Pancreatic cancer [2C10] [12]
Pemetrexed DMMX2E6 Moderate Decreased renal excretion of Cidofovir caused by Pemetrexed mediated nephrotoxicity. Pleural mesothelioma [2C26] [14]
Ketorolac DMI4EL5 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Ketorolac. Postoperative inflammation [1A00-CA43] [12]
Bromfenac DMKB79O Major Increased risk of nephrotoxicity by the combination of Cidofovir and Bromfenac. Postoperative inflammation [1A00-CA43] [12]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Cidofovir and Temsirolimus. Renal cell carcinoma [2C90] [12]
Colistimethate DMZ9BMU Major Increased risk of nephrotoxicity by the combination of Cidofovir and Colistimethate. Respiratory infection [CA07-CA4Z] [12]
Salsalate DM13P4C Major Increased risk of nephrotoxicity by the combination of Cidofovir and Salsalate. Rheumatoid arthritis [FA20] [12]
Meloxicam DM2AR7L Major Increased risk of nephrotoxicity by the combination of Cidofovir and Meloxicam. Rheumatoid arthritis [FA20] [12]
Sulindac DM2QHZU Major Increased risk of nephrotoxicity by the combination of Cidofovir and Sulindac. Rheumatoid arthritis [FA20] [12]
Penicillamine DM40EF6 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Penicillamine. Rheumatoid arthritis [FA20] [12]
Celecoxib DM6LOQU Major Increased risk of nephrotoxicity by the combination of Cidofovir and Celecoxib. Rheumatoid arthritis [FA20] [12]
Oxaprozin DM9UB0P Major Increased risk of nephrotoxicity by the combination of Cidofovir and Oxaprozin. Rheumatoid arthritis [FA20] [12]
Flurbiprofen DMGN4BY Major Increased risk of nephrotoxicity by the combination of Cidofovir and Flurbiprofen. Rheumatoid arthritis [FA20] [12]
Sulfasalazine DMICA9H Major Increased risk of nephrotoxicity by the combination of Cidofovir and Sulfasalazine. Rheumatoid arthritis [FA20] [12]
Fenoprofen DML5VQ0 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Fenoprofen. Rheumatoid arthritis [FA20] [12]
Tolmetin DMWUIJE Major Increased risk of nephrotoxicity by the combination of Cidofovir and Tolmetin. Rheumatoid arthritis [FA20] [12]
Bacitracin DM5OHYE Major Increased risk of nephrotoxicity by the combination of Cidofovir and Bacitracin. Skin and skin-structure infection [1F28-1G0Z] [12]
Cyclophosphamide DM4O2Z7 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [12]
Ifosfamide DMCT3I8 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [12]
Cisplatin DMRHGI9 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [12]
Telavancin DM58VQX Major Increased risk of nephrotoxicity by the combination of Cidofovir and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [12]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Cidofovir and Sirolimus. Transplant rejection [NE84] [12]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Cidofovir and Tacrolimus. Transplant rejection [NE84] [12]
Olsalazine DMZW9HA Major Increased risk of nephrotoxicity by the combination of Cidofovir and Olsalazine. Ulcerative colitis [DD71] [12]
Plazomicin DMKMBES Major Increased risk of nephrotoxicity by the combination of Cidofovir and Plazomicin. Urinary tract infection [GC08] [12]
Ganciclovir DM1MBYQ Major Increased risk of nephrotoxicity by the combination of Cidofovir and Ganciclovir. Virus infection [1A24-1D9Z] [12]
Valaciclovir DMHKS94 Major Increased risk of nephrotoxicity by the combination of Cidofovir and Valaciclovir. Virus infection [1A24-1D9Z] [12]
Valganciclovir DMS2IUH Major Increased risk of nephrotoxicity by the combination of Cidofovir and Valganciclovir. Virus infection [1A24-1D9Z] [12]
Aciclovir DMYLOVR Major Increased risk of nephrotoxicity by the combination of Cidofovir and Aciclovir. Virus infection [1A24-1D9Z] [12]
⏷ Show the Full List of 69 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cidofovir 375mg/5ml injectable 375mg/5ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
2 Cidofovir FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5.
10 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
11 Cerner Multum, Inc. "Australian Product Information.".
12 Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA.
13 Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
14 Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.